Technical Analysis for CALT - Calliditas Therapeutics AB
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Historical CALT trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Buy Signal | Bullish | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
200 DMA Resistance | Bearish | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 2.57% | |
200 DMA Resistance | Bearish | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Down 1% | 1 day ago |
60 Minute Opening Range Breakdown | 1 day ago |
Fell Below Previous Day's Low | 1 day ago |
3x Volume Pace | 1 day ago |
2x Volume Pace | 1 day ago |
Free Daily (Stock) Chart Reading
- Earnings date: ???
Calliditas Therapeutics AB Description
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceutical Industry Pharmaceutical Products Pharmacy Health Sciences Medication Kidney Disease Kidney Diseases Renal Disease Iga Nephropathy Pharmaceutics
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 38.0 |
52 Week Low | 19.0 |
Average Volume | 35,074 |
200-Day Moving Average | 27.66 |
50-Day Moving Average | 29.11 |
20-Day Moving Average | 28.52 |
10-Day Moving Average | 27.66 |
Average True Range | 0.92 |
ADX | 22.83 |
+DI | 15.45 |
-DI | 31.29 |
Chandelier Exit (Long, 3 ATRs ) | 27.43 |
Chandelier Exit (Short, 3 ATRs ) | 29.55 |
Upper Bollinger Band | 30.63 |
Lower Bollinger Band | 26.41 |
Percent B (%b) | 0.26 |
BandWidth | 14.82 |
MACD Line | -0.60 |
MACD Signal Line | -0.52 |
MACD Histogram | -0.0823 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 27.97 | ||||
Resistance 3 (R3) | 27.92 | 27.71 | 27.89 | ||
Resistance 2 (R2) | 27.71 | 27.59 | 27.74 | 27.86 | |
Resistance 1 (R1) | 27.61 | 27.52 | 27.66 | 27.66 | 27.84 |
Pivot Point | 27.40 | 27.40 | 27.43 | 27.43 | 27.40 |
Support 1 (S1) | 27.30 | 27.28 | 27.35 | 27.35 | 27.16 |
Support 2 (S2) | 27.09 | 27.21 | 27.12 | 27.14 | |
Support 3 (S3) | 26.99 | 27.09 | 27.11 | ||
Support 4 (S4) | 27.04 |